109 related articles for article (PubMed ID: 23179373)
1. A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin.
Pollock RF; Curtis BH; Smith-Palmer J; Valentine WJ
Adv Ther; 2012 Dec; 29(12):1051-66. PubMed ID: 23179373
[TBL] [Abstract][Full Text] [Related]
2. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.
Pollock RF; Curtis BH; Valentine WJ
J Med Econ; 2012; 15(4):766-75. PubMed ID: 22413830
[TBL] [Abstract][Full Text] [Related]
3. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
Valentine WJ; Palmer AJ; Lammert M; Nicklasson L; Foos V; Roze S
Curr Med Res Opin; 2005 Dec; 21(12):2063-71. PubMed ID: 16368057
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.
Bruhn D; Martin AA; Tavares R; Hunt B; Pollock RF
J Med Econ; 2016 Jul; 19(7):672-83. PubMed ID: 26882484
[TBL] [Abstract][Full Text] [Related]
9. New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Standl E; Owen DR
Diabetes Care; 2016 Aug; 39 Suppl 2():S172-9. PubMed ID: 27440830
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study.
Yang L; Christensen T; Sun F; Chang J
Value Health; 2012; 15(1 Suppl):S56-9. PubMed ID: 22265068
[TBL] [Abstract][Full Text] [Related]
12. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
Pollock RF; Valentine WJ; Marso SP; Andersen A; Gundgaard J; Hallén N; Tutkunkardas D; Magnuson EA; Buse JB;
Appl Health Econ Health Policy; 2019 Oct; 17(5):615-627. PubMed ID: 31264138
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes.
Gordon J; McEwan P; Sabale U; Kartman B; Wolffenbuttel BH
J Med Econ; 2016 Dec; 19(12):1167-1174. PubMed ID: 27356188
[TBL] [Abstract][Full Text] [Related]
15. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
Palmer JL; Goodall G; Nielsen S; Kotchie RW; Valentine WJ; Palmer AJ; Roze S
Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
[TBL] [Abstract][Full Text] [Related]
17. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
Pfohl M; Schädlich PK; Dippel FW; Koltermann KC
J Med Econ; 2012; 15 Suppl 2():14-27. PubMed ID: 22812690
[TBL] [Abstract][Full Text] [Related]
18. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK.
Valentine WJ; Curtis BH; Pollock RF; Van Brunt K; Paczkowski R; Brändle M; Boye KS; Kendall DM
Diabetes Res Clin Pract; 2015 Jul; 109(1):95-103. PubMed ID: 25989713
[TBL] [Abstract][Full Text] [Related]
19. An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK.
Pratoomsoot C; Smith HT; Kalsekar A; Boye KS; Arellano J; Valentine WJ
Diabet Med; 2009 Aug; 26(8):803-14. PubMed ID: 19709151
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
